Endocrine Abstracts

Objective: Dapagliflozin, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, reduces hyperglycemia and body weight by inhibiting renal glucose reabsorption. However, only a few studies have shown the glycemic efficacy on a combination of dapagliflozin in type 2 diabetic patients in Korean. We evaluated the efficacy and safety of glucose control on a combination of dapagliflozin in people with type 2 diabetes in Korea.

Methods: This is a retrospective, observational study, data from 61 patients with 12 months of dapagliflozin(10mg once-daily) therapy were analyzed, visited medical center from January 2015 to July 2016. We had divided into three treatment groups: first group was dual combination of dapagliflozin and metformin (Group 1); second group was triple combination of dapagliflozin and metformin with sulfonylurea or dipeptidyl-peptidase IV(DPP-4) inhibitors (Group 2); third group was quadriple combination of dapagliflozin, metformin and sulfonylurea with DPP-4inhibitors (Group 3).

Results: Of 61 type 2 diabetic sub-jects, 32 (52.5%) were men and 29 (47.5%) were women. Mean age and duration of DM were 58.5±9.6 years and 11.4±5.6 years respectively; mean body weight and BMI were 72.6±12.1 kg and 27.3±3.6 kg/m² respectively. Mean HbA1c and 2-hour postprandial glucose levels were 7.6±1.0% and 194.2±69.8 mg/dl respectively. After 12 months, Dapagliflozin leads to improvement in HbA1, 2-hour postprandial glucose(PP2) in each group. In total, the reductions in HbA1c and PP2 levels were −0.61±0.82% (P=0.000) and −35.4±62 mg/dl (P=0.000) respectively. In group 1, the reduction rates in HbA1c and PP2 levels were 0.39±0.80% (P=0.093) and −19.2±41.0 mg/dl (P=0.152) respectively. In group 2, the reduction in HbA1c and PP2 levels were -0.93±1.0% (P=0.018) and −63.1±90.6 mg/dl (P=0.034) respectively. In group 3 the reduction in HbA1c and PP2 levels were −0.65±0.71% (P=0.002) and −37.9±61.4 mg/dl (P=0.001) respectively. There were no serious adverse event including hypoglycemia in dapagliflozin group.

Conclusions: In patients with type 2 diabetes, a combination of dapagliflozin improved glycemic control and reduced body weight reduction with safety.